UBS Group
NRSNW icon

UBS Group’s NeuroSense Therapeutics Warrant NRSNW Stock Holding History

UBS Group’s Portfolio NRSNW Stock Details NRSNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$73 Hold
1,163
– – ﹤0.01% 10149
2026
Q1 		$64 Hold
1,163
– – ﹤0.01% 10178
2025
Q4 		$291 Sell
1,163
-117
-9% -$42 ﹤0.01% 10055
2025
Q3 		$397 Sell
1,280
-190
-13% -$114 ﹤0.01% 9695
2025
Q2 		$932 Sell
1,470
-1,371
-48% -$535 ﹤0.01% 9704
2025
Q1 		$582 Buy
2,841
+2,747
+2,922% +$718 ﹤0.01% 9724
2024
Q4 		$41 Sell
94
-106
-53% -$28 ﹤0.01% 9723
2024
Q3 		$28 Sell
200
-405
-67% -$69 ﹤0.01% 9284
2024
Q2 		$125 Buy
+605
New +$139 ﹤0.01% 9131
2023
Q4 		– Sell
-3,802
Closed -$422 – 9715
2023
Q3 		$422 Buy
+3,802
New +$692 ﹤0.01% 8507
2023
Q1 		– Sell
-798
Closed -$128 – 10113
2022
Q4 		$128 Sell
798
-1,160
-59% -$293 ﹤0.01% 10370
2022
Q3 		$0 Buy
+1,958
New +$506 ﹤0.01% 10727
2022
Q1 		– Sell
-4,491
Closed -$4K – 10687
2021
Q4 		$4K Buy
+4,491
New +$4K ﹤0.01% 9532

Other funds holding NRSNW

EAM
Empery Asset Management New York $86.5M AUM
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

UBS Group's NRSNW Position: Q2 2026 in Review

UBS Group held its NeuroSense Therapeutics Warrant (NRSNW) position steady in Q2 2026 at 1,163 shares worth $73. The position accounts for ﹤0.01% of the portfolio, ranked #10149.

UBS Group first reported a position in NRSNW in Q4 2021 and has held it in 13 quarters since. The position peaked at $4K in Q4 2021. 3 funds tracked by Wall St. Rank hold NRSNW as of Q2 2026.

  • UBS Group held 1,163 shares of NeuroSense Therapeutics Warrant worth $73 as of Q2 2026.
  • UBS Group left its NeuroSense Therapeutics Warrant share count unchanged in Q2 2026.
  • NeuroSense Therapeutics Warrant made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #10149 holding.
  • UBS Group first reported a position in NeuroSense Therapeutics Warrant in Q4 2021 and has held it in 13 quarters since.
  • UBS Group's NeuroSense Therapeutics Warrant position peaked at $4K in Q4 2021.
  • 3 funds tracked by Wall St. Rank held NeuroSense Therapeutics Warrant as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.